财商
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manif
Significant unmet need remains for 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burden
Enpatoran, an oral TLR7/8 inhibi...